Amedisys Inc (NASDAQ:AMED) – Equities researchers at Jefferies Group lifted their FY2017 earnings per share (EPS) estimates for shares of Amedisys in a report issued on Wednesday. Jefferies Group analyst B. Tanquilut now expects that the health services provider will earn $2.20 per share for the year, up from their prior forecast of $2.05. Jefferies Group currently has a “Buy” rating and a $57.00 price objective on the stock. Jefferies Group also issued estimates for Amedisys’ FY2018 earnings at $2.45 EPS.

Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The firm had revenue of $378.80 million for the quarter, compared to analyst estimates of $380.80 million. Amedisys had a return on equity of 12.60% and a net margin of 3.16%. The company’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.42 EPS.

TRADEMARK VIOLATION WARNING: “FY2017 EPS Estimates for Amedisys Inc Increased by Jefferies Group (AMED)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/28/fy2017-eps-estimates-for-amedisys-inc-increased-by-jefferies-group-amed.html.

Several other research firms have also issued reports on AMED. Benchmark Co. restated a “hold” rating and issued a $57.00 price objective (up previously from $50.00) on shares of Amedisys in a research note on Wednesday, May 3rd. Zacks Investment Research lowered Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Royal Bank Of Canada restated a “hold” rating and issued a $56.00 price objective on shares of Amedisys in a research note on Monday, June 5th. Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective on the stock in a research note on Wednesday, May 3rd. Finally, BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $56.50.

Amedisys (AMED) traded down 0.57% during mid-day trading on Friday, reaching $46.71. The company’s stock had a trading volume of 623,373 shares. The company has a 50 day moving average of $60.87 and a 200-day moving average of $54.00. Amedisys has a 52-week low of $34.58 and a 52-week high of $65.91. The stock has a market cap of $1.58 billion, a PE ratio of 34.60 and a beta of 0.94.

In other news, insider Scott G. Ginn sold 23,828 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $58.62, for a total value of $1,396,797.36. Following the transaction, the insider now owns 13,018 shares of the company’s stock, valued at $763,115.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jake L. Netterville sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the completion of the transaction, the director now directly owns 77,499 shares in the company, valued at approximately $4,649,940. The disclosure for this sale can be found here. Insiders sold 56,828 shares of company stock worth $3,350,922 in the last ninety days. 2.80% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of AMED. Ameritas Investment Partners Inc. purchased a new position in Amedisys during the first quarter valued at approximately $123,000. State of Alaska Department of Revenue increased its stake in shares of Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock worth $157,000 after buying an additional 70 shares in the last quarter. CIBC Asset Management Inc bought a new stake in shares of Amedisys during the second quarter worth about $230,000. Redmile Group LLC bought a new stake in shares of Amedisys during the first quarter worth about $247,000. Finally, Suntrust Banks Inc. increased its stake in shares of Amedisys by 2.0% in the first quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock worth $279,000 after buying an additional 107 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.